Arun Iyer, a Ph.D. and assistant professor of pharmaceutical sciences at Wayne State University, has received a three-year, $611,475 award to research and look for new treatment strategies for renal cell carcinoma, a kidney cancer.
Renal cell carcinoma is the most common form of kidney cancer and is one of the 10 leading causes of cancer death in the U.S. Every year, more than 60,000 people are diagnosed with the disease, and more than 14,000 people die from it.
“Renal cell carcinoma is difficult to treat because it is resistant to many of the current therapies available,” Iyer says.
Iyer says the cancer often is diagnosed in the late stages, making it more resistant to current treatments. Because of this, newer combinations of targeted therapies are needed, including better ways of drug delivery as well as imaging and diagnosis. Preliminary results of his study are promising, he says, and the funding will be used to validate the team’s initial findings and may result in improved drug delivery efficiency, effectiveness, and safety.
Project co-investigators include Samaresh Sau, Ph.D, a senior research scientist in the department of pharmaceutical science, Arun Rishi, Ph.D, a professor of oncology, and Ulka Vaishampayan, M.D, a physician scientist collaborator and chair of the Eisenberg Center of Translational Therapeutics at the Karmanos Cancer Institute.
The funds come from the Idea Development Award as an Early Career Investigator from the Department of Defense Kidney Cancer Research Program.